Eli Lilly's bid for Orna Therapeutics cleared by Australian watchdog
( May 4, 2026, 06:51 GMT | Official Statement) -- MLex Summary: Eli Lilly's proposal to acquire 100 percent of the issued shares in Orna Therapeutics has been cleared by Australia's competition watchdog. In a Monday statement, the Australian Competition and Consumer Watchdog said the merged company would likely still face competition from alternative suppliers developing relevant therapies in the early stages of development. Eli Lilly is a US-based pharmaceutical company, which has an Australian subsidiary that registers and markets medicines in Australia. Orna Therapeutics is a US-based pre-clinical biotechnology company. Statement follows. Determination attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.